Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Next Status Conference in Federal Actos Bladder Cancer Litigation
Date:9/14/2013

New York, NY (PRWEB) September 14, 2013

At least 2,500 Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) that allege extended use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, the Actos bladder cancer litigation will convene its next Status Conference on September 26, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm continues to be contacted by Actos users who developed bladder cancer after using this medication for at least 12 months. We are pleased to see this proceeding moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.

Actos Bladder Cancer Litigation
According to court documents, all of the Actos bladder cancer lawsuits pending in the Western District of Louisiana claim that Takeda Pharmaceuticals and other defendants concealed their knowledge of the bladder cancer risk associated with Actos, and failed to provide adequate warnings to the public and medical community. The federal litigation’s first bellwether trial will begin on January 27, 2014, while its second Actos bladder cancer trial will commence on April 14, 2014.

Additional Actos lawsuits involving bladder cancer allegations are also pending in various state courts. According to court documents, the nation’s second trial of an Actos bladder cancer claim is currently underway in Maryland State Court. The lawsuit, which was filed on behalf of an Actos user who died of bladder cancer last year, alleges that Takeda knew as early as 2005 that research had linked prolonged use of the drug to the disease cancer, but waited six years to issue a public warning. The complaint further alleges that the company’s conduct was motivated by a desire to increase Actos sales. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

The first trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, court documents indicate that the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation involving Actos bladder cancer claims began to move forward in June 2011, after the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year could increase a patient’s risk for the disorder. At that time, the FDA mandated that new information about the association between Actos and bladder cancer be added to the drug’s label.

Patients who took Actos for an extended period of time and later developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing
the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11123365.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuit Filed By Wright & Schulte on Behalf of Ohio Man Alleges Extended Use of Type-2 Diabetes Drug Caused Him to Develop Bladder Cancer
3. Actos Bladder Cancer Lawsuits Move Forward, with Issuance of New Order in Federal Actos Litigation, Bernstein Liebhard LLP Reports
4. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
5. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
6. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
7. Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
8. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
9. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
10. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
11. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
Breaking Medicine Technology: